Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00135382
First received: August 25, 2005
Last updated: January 27, 2010
Last verified: January 2010
  Purpose

The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a protease inhibitor (PI)-based regimen to an efavirenz-based regimen while maintaining virologic control, as evaluated by the proportion of subjects who continue to have plasma HIV-1 levels < 50 copies/mL. In addition, a simplified once-daily regimen will improve adherence and quality of life.


Condition Intervention Phase
HIV Infections
Drug: Videx EC
Drug: Epivir
Drug: Sustiva
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3 Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Efficacy at week 48

Secondary Outcome Measures:
  • Safety, tolerability and efficacy at weeks (wks) 24 and 48; Effect on lipids at wks 24 and 48; Adherence, quality of life changes, treatment satisfaction and preference at wks 12, 24 and 48

Estimated Enrollment: 254
Study Start Date: June 2002
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Detailed Description:

Patients randomized to the non Videx enteric coated (ddl EC)+lamivudine (3TC)+efavirenz (EFV) arm would continue their baseline nucleoside reverse transcriptase inhibitors (NRTIs) on study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented HIV infection
  • ≥ 18 years of age and weight at least 40kg
  • Two plasma HIV RNA levels < 50 copies/mL during the qualification and screening period
  • Patients receiving a PI and ≥ 2 NRTIs

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Documented virologic failure while on their first PI-based antiretroviral (ARV) regimen
  • Active AIDS-defining opportunistic infection or disease
  • Proven or suspected acute hepatitis within 30 days prior to study entry
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00135382

  Hide Study Locations
Locations
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
Beverly Hills, California, United States
Local Institution
Fountain Valley, California, United States
Local Institution
Long Beach, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
San Diego, California, United States
Local Institution
San Francisco, California, United States
Local Institution
Tarzana, California, United States
Local Institution
W. Hollywood, California, United States
United States, Colorado
Local Institution
Denver, Colorado, United States
United States, Connecticut
Local Institution
Norwalk, Connecticut, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
Atlantis, Florida, United States
Local Institution
Daytona Beach, Florida, United States
Local Institution
Ft. Lauderdale, Florida, United States
Local Institution
Jacksonville, Florida, United States
Local Institution
Miami, Florida, United States
Local Institution
Miami Beach, Florida, United States
Local Institution
North Miami, Florida, United States
Local Institution
Orlando, Florida, United States
Local Institution
Plantation, Florida, United States
Local Institution
Safety Harbor, Florida, United States
Local Institution
South Miami, Florida, United States
Local Institution
Tampa, Florida, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
Local Institution
Decatur, Georgia, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Massachusetts
Local Institution
Boston, Massachusetts, United States
Local Institution
Springfield, Massachusetts, United States
United States, Missouri
Local Institution
Kansas City, Missouri, United States
Local Institution
St. Louis, Missouri, United States
United States, New Jersey
Local Institution
East Orange, New Jersey, United States
Local Institution
Newark, New Jersey, United States
Local Institution
Union, New Jersey, United States
United States, New York
Local Institution
Brooklyn, New York, United States
Local Institution
Manhasset, New York, United States
Local Institution
Mt. Vernon, New York, United States
Local Institution
New York, New York, United States
Local Institution
Stony Brook, New York, United States
Local Institution
Valhalla, New York, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, South Carolina
Local Institution
Columbia, South Carolina, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
United States, Virginia
Local Institution
Hampton, Virginia, United States
United States, Wisconsin
Local Institution
Milwaukee, Wisconsin, United States
Puerto Rico
Local Institution
Ponce, Puerto Rico
Local Institution
Rio Piedras, Puerto Rico
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00135382     History of Changes
Other Study ID Numbers: AI266-406
Study First Received: August 25, 2005
Last Updated: January 27, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:
HIV/AIDS

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Protease Inhibitors
HIV Protease Inhibitors
Lamivudine
Efavirenz
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on April 17, 2014